Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688399'
s Net Margin % Range Over the Past 10 Years
Min: -92.72 Med: 25.23 Max: 47.11
Current: -10.05
SHSE:688399's Net Margin % is ranked better than 66.24% of 942
companies
in the Biotechnology industry
Industry Median: -88.295
vs SHSE:688399: -10.05
Jiangsu Bioperfectus Technologies Co (SHSE:688399) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Jiangsu Bioperfectus Technologies Co Net Margin % Related Terms
Jiangsu Bioperfectus Technologies Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Bioperfectus Technologies Co Net Margin % Chart
SHSE:688399 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Jiangsu Bioperfectus Technologies Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Bioperfectus Technologies Co Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jiangsu Bioperfectus Technologies Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Jiangsu Bioperfectus Technologies Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Bioperfectus Technologies Co (SHSE:688399) has a Net Margin % of 26.88% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Jiangsu Bioperfectus Technologies Co and its competitors. This is near median its historical median of 25.23. According to the industry distribution chart, Jiangsu Bioperfectus Technologies Co ranks #318 out of 942 companies in the Biotechnology industry, placing it in the top 33.8%.
Is Jiangsu Bioperfectus Technologies Co's Net Margin % too high?
Jiangsu Bioperfectus Technologies Co's current Net Margin % of 26.88% is near median its 10-year median of 25.23. Based on the distribution chart, Jiangsu Bioperfectus Technologies Co ranks #318 out of 942 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Jiangsu Bioperfectus Technologies Co has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Bioperfectus Technologies Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jiangsu Bioperfectus Technologies Co ranks #318 out of 942 companies for Net Margin %. This puts Jiangsu Bioperfectus Technologies Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Jiangsu Bioperfectus Technologies Co and its competitors. Jiangsu Bioperfectus Technologies Co's current Net Margin % is 26.88%, which is near median its own 10-year median of 25.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Bioperfectus Technologies Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Bioperfectus Technologies Co (SHSE:688399) is currently considered Fairly Valued. The stock's GF Value™ is ¥28.93, compared to a current price of ¥29.89 — trading 3.3% above its estimated fair value. The current Net Margin % is 26.88%, which is near median its 10-year median of 25.23. Jiangsu Bioperfectus Technologies Co's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Jiangsu Bioperfectus Technologies Co (SHSE:688399), the current Net Margin % is 26.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Bioperfectus Technologies Co (SHSE:688399) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Bioperfectus Technologies Co stock appears to be overvalued.
The current stock price of ¥29.89 is trading 3.3% above its estimated GF Value™ of ¥28.93.
GuruFocus considers Jiangsu Bioperfectus Technologies Co to be Fairly Valued.
Key valuation signals for SHSE:688399:
Net Margin %: 26.88% (near median its 10-year median of 25.23)
GF Value™: ¥28.93 vs. price of ¥29.89 (3.3% above fair value)
No single metric tells the full story. See the SHSE:688399 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Bioperfectus Technologies Co Business Description
Jiangsu Bioperfectus Technologies Co Ltd is engaged in product development, production and sales of disease prevention and control, female genital micro-ecological testing and tumor screening. Its products portfolio includes Fever respiratory pathogen detection series, Fever with a rash pathogen test series, Fever with bleeding pathogen test series, Foodborne diseases and diarrheal pathogen detection and Other types of pathogen detection series.
63GF Score
Get the complete analysis for SHSE:688399
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688399 has been successfully added to your 
